Syndax Pharmaceuticals announces positive results from BEAT AML and AUGMENT-102 trials of menin inhibitor revumenib for acute leukemias, showing high CRc rates and safety profile.
Syndax Pharmaceuticals announced updated positive results from multiple combination trials of revumenib, a menin inhibitor for acute leukemias. The BEAT AML trial showed a 96% CRc rate, and AUGMENT-102 trial had a 52% CRc rate in a predominantly pediatric population. Both trials demonstrated revumenib's safety profile and potential to enhance standard of care agents. Syndax plans a pivotal trial in front-line, newly diagnosed patients by year-end 2024.
June 14, 2024
3 Articles